AU616283B2

AU616283B2 – Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
– Google Patents

AU616283B2 – Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
– Google Patents
Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them

Download PDF
Info

Publication number
AU616283B2

AU616283B2
AU37287/89A
AU3728789A
AU616283B2
AU 616283 B2
AU616283 B2
AU 616283B2
AU 37287/89 A
AU37287/89 A
AU 37287/89A
AU 3728789 A
AU3728789 A
AU 3728789A
AU 616283 B2
AU616283 B2
AU 616283B2
Authority
AU
Australia
Prior art keywords
acid
general formula
radical
ring
hydrogen
Prior art date
1988-07-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU37287/89A
Other versions

AU3728789A
(en

Inventor
Elmar Bosies
Harald Zilch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Roche Diagnostics GmbH

Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1988-07-05
Filing date
1989-07-04
Publication date
1991-10-24

1989-07-04
Application filed by Boehringer Mannheim GmbH
filed
Critical
Boehringer Mannheim GmbH

1990-01-11
Publication of AU3728789A
publication
Critical
patent/AU3728789A/en

1991-10-24
Application granted
granted
Critical

1991-10-24
Publication of AU616283B2
publication
Critical
patent/AU616283B2/en

2009-07-04
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/28—Phosphorus compounds with one or more P—C bonds

C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)

C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups

C07F9/3839—Polyphosphonic acids

C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N…..H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N…..O, N…..S, N…..C(=X)- (X =O, S), N…..N, N…C(=X)…N (X =O, S)

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/28—Phosphorus compounds with one or more P—C bonds

C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)

C07F9/40—Esters thereof

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P3/00—Drugs for disorders of the metabolism

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P3/00—Drugs for disorders of the metabolism

A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis

A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/28—Phosphorus compounds with one or more P—C bonds

C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)

C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups

C07F9/3839—Polyphosphonic acids

C07F9/386—Polyphosphonic acids containing hydroxy substituents in the hydrocarbon radicals

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom

C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom

C07F9/572—Five-membered rings

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom

C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom

C07F9/572—Five-membered rings

C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom

C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom

C07F9/576—Six-membered rings

C07F9/59—Hydrogenated pyridine rings

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom

C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom

C07F9/576—Six-membered rings

C07F9/60—Quinoline or hydrogenated quinoline ring systems

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom

C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms

C07F9/6503—Five-membered rings

C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom

C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms

C07F9/6509—Six-membered rings

C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom

C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms

C07F9/6533—Six-membered rings

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM

C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System

C07F9/02—Phosphorus compounds

C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom

C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms

C07F9/6544—Six-membered rings

Abstract

Compounds of the formula I

in which R1-R9, m, n and X have the meaning indicated in the claims, process for their preparation and medicines containing these compounds for the treatment of disturbances of calcium metabolism.

Description

.r 1/ 616 283 COMMONWEALTH OF AUSTRALIA PATENTS ACT 1952 COMPLETE SPECIFICATION NAME ADDRESS OF APPLICANT: t r t 4 4 I Boehringer Mannheim GmbH Sandhofer Strasse 112-132 D-6800 Mannheim-Waldhof Federal Republic of Germany NAME(S) OF INVENTOR(S): Elhar BOSIES Harald ZILCH ADDRESS FOR SERVICE: DAVIES COLLISON Patent Attorneys 1 Little Collins Street, Melbourne, 3000.
COMPLETE SPECIFICATION FOR THE INVENTION ENTITLED: Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them I I The following statement is a full performing it known to me/us:description of this invention, including the best method of -2- The present invention is concerned with new diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them.
Federal Republic of Germany Patent Specification No. 18 13 659 describes diphosphonic acid derivatives of which l-hydroxyethane-l,l-diphosphonic acid has achieved importance for the treatment of Paget’s disease.
In Federal Republic of Germany Patent Specification No. 25 34 391 are described aminoalkane-l,ldiphosphonic acids which can be substituted on the 0 a0 nitrogen atom by C 1
-C
3 -alkyl radicals and which have -o an action on the calcium metabolism.
.j:1 15 Surprisingly, we have now found that aminoalkanej «1,1-diphosphonic acids in which the alkyl chain is interrupted by an oxygen atom display a distinctly more marked action on the calcium metabolism than the com- 00oO0. pounds hitherto known. Thus, these compounds are 20 especially suitable for a wide treatment of calcium 9′ metabolism disturbances. In particular, they can be used especially well in cases where the build up and breakdown of bone is disturbed, i.e. they are suitable for the treatment of diseases of the skeletal system, for example osteoporosis, Paget’s disease, Bechterew’s disease and the like. On the basis of these properties, they can also be used for the therapy of bone f- S -3metastases, urolithiasis and for the prevention of heteroptopic ossification. Furthermore, due to their r influence on the calcium metabolism, they also provide a basis for the treatment of rheumatoid arthritis, of osteoarthritis and of degenerative arthrosis.
Thus, according to the present invention, there are provided diphosphonates of the general formula:- 0 R R3 R R P(OR 9 2 i 10 N C C (CH2 -0-(CH2) n C C X (I) 2 R m 2n I 0
R
4
R
6 R P(OR 9) 2 0 wherein R and R 2 independently of one another, are hydrogen atoms, straight-chained or branched, saturated or unsaturated alkyl radicals containing up to 9 carbon atoms which can optionally be substituted by hydroxyl, C 1
-C
5 -alkoxy or C1-C5-alkylthio, a phenyl or
C
5
-C
7 -cycloalkyl ring, whereby the phenyl moiety can optionally be substituted by C 1
-C
5 -alkyl, C 1
-C
5 -alkoxy, hydroxyl or halogen, or are C 5
-C
7 -cycloalkyl or phenyl radicals, R 3 is a hydrogen atom, a straight-chained or branched C 1
-C
5 -alkyl radical, which is optionally substituted by hydroxyl, C 1
-C
5 -alkoxy, C 1
-C
5 -alkylthio, mercapto, phenyl, 3-indolyl or 4-imidazolyl, or a phenyl radical optionally substituted by hydroxyl or
C
1
-C
5 -alkoxy, R 4
R
6
R
8 and R 9 independently of one another, are hydrogen atoms or C 1
-C
5 -alkyl radicals,
I-
-4and R 7 independently of one another, are hydrogen atoms, C 1
-C
5 -alkyl radicals or phenyl radicals optionally substituted by hydroxyl or C 1
-C
5 -alkoxy, X is a hydrogen atom, a hydroxyl group or an -NR 10
R
1 I radical, whereby R 1 0 and R 1 1 independently of one another, are hydrogen atoms or C -C 5 -alkyl radicals and m and n are 0 or 1, whereby R 1 and R 2 together with the nitrogen atom to which they are attached, can form a mono- or bicyclic ring system containing 4 to 9 carbon atoms which is partly or wholly hydrogenated and optionally substituted by hydroxyl, C 1
-C
5 -alkyl or C 1
-C
5 -alkoxy and/or, in the case of a monocyclic radical, can be interrupted by an oxygen, nitrogen or sulphur atom, R1 and R 3 together with the carbon and nitrogen atoms to i 15 which they are attached, can form a five- or six- SI membered ring which can optionally be condensed by a further six-membered ring, R 1 and R 5 together with i the carbon and nitrogen atoms to which they are attached, as well as the carbon atom lying therebetween, can form a five- or six-membered ring, R 3 and R, together with the carbon atom to which they are attached, can form a five- or six-membered ring, R 5 and
R
6 together with the carbon atoms to which they are attached, can form a five- or six-membered ring, R 5 and
R
6 together with the carbon atom to which they are attached, can form a five- or six-membered ring and R and R 8 together with the carbon atom to which they are r ~ri i -2 t r i t I I /i I it LAi attached, can form a five- or six-membered ring; as well as the pharmacologically acceptable salts thereof.
By C 1
-C
5 -alkyl radicals are preferably to be understood methyl, ethyl, isopropyl and isobutyl radicals.
C
1
-C
5 -alkoxy and alkylthio radicals are preferably methoxy and methylthio radicals, respectively.
The C5-C 7 -cycloalkyl radical is preferably a cyclohexyl radical.
Halogen is to be understood to be especially a chlorine or bromine atom.
The alkyl chains with up to 9 carbon atoms in the case of R 1 and R 2 are preferably methyl, ethyl, isopropyl, isobutyl, sec.-butyl, n-pentyl, n-nonyl, allyl 15 or methallyl radicals.
By an alkyl radical substituted by an optionally substituted phenyl radical is to be understood especially a benzyl radical.
The -NR 10
R
11 radical is preferably an amino, dimethylamino or diethylamino radical.
If R1 and R 2 together with the nitrogen atom to which they are attached, form a ring, then this is preferably understood to be a pyrrolidine, piperidine, di- or octahydroisoindoline or decahydroquinoline ring.
A ring interrupted by a heteroatom is preferably a piperazine, morpholine or thiamorpholine ring.
When R1 and R 3 together with the nitrogen atom -6to which they are attached, form a ring, then this is to be understood to be, inter alia, a pyrrolidine, piperidine or octahydroindole ring substituted in the 2-position.
When R 1 and R 5 together with the carbon and nitrogen atoms to which they are attached, as well as the carbon atom lying therebetween, form a ring, this ring is preferably a pyrrolidine cr piperidine ring substituted in the 3-position.
When R and R or R 5 and R 6 or R 7 and R 8 together with the carbon atom to which they are attached, form a ring, this is preferably a cyclopentyl ring.
If R and R 6 together with the carbon atoms to 4 6 which they are attached, form a ring, then this is preferably a cyclohexyl or cyclopentyl ring.
i X is preferably a hydrogen atom or a hydroxyl group.
Preferred compounds of formula I are compounds wherein R is hydrogen or methyl, R 2 is hydrogen or methyl, R 3 is hydrogen or C -C 5 -alkyl, R 4 is hydrogen or methyl, R 5 is hydrogen or methyl, R 6 is hydrogen, R is hydrogen, R8 is hydrogen, R 9 is hydrogen, m is zero or 1, n is zero and X is a hydroxyl group -6awhereby R I and R 6 together with the nitrogen atom form a morpholine ring, R 1 and R 3 together with the carbon and nitrogen atoms to which they are attached form a pyrrolidine or piperidine ring, R and R together with the carbon and nitrogen atoms 5 to which they are attached form a piperidine ring,
R
4 und R 6 together with the carbon atom to which they are attached form a cyclohexyl ring and R and R 6 together with the carbon atom to which they are attached form a spiro-cyclopentane ring.
Asymmetric carbon atoms can have the R- or Sconfiguration and the compouqds can be present in the optically-active form or as a racemic mixture. They are also within the scope of the present invention.
Compounds of general formula I are prepared by known processes and preferably by I. mono- or dialkylating a compound of the general formula: -7- 0 S R 3
R
5
R
7
P(OR
9 2 N C C (CH 2 )m-0-(CH 2 C C X (II) Hn R R R P(OR 9 2 0 in which R 1
R
3
-R
9 X, m and n have the above-given 13 9 meanings, and optionally saponifying the resulting 1 tetraester to give the corresponding diester or acid of general formula I; or II. when X in general formula I is a hydroxyl group, j 10 a) reacting a carboxylic acid of the general formula: RI R R 5
R
R R R N C C (CH 2 )m-O-(CH 2 C COOH (III) R i
II
R
4
R
6
R
8 in which R -R 8 m and n have the above-given meanings, 1 8 with a mixture of phosphorous acid or phosphoric acid and a phosphorus halide or phosphorus oxyhalide and j subsequently saponifying to the free diphosphonic acid; or b) reacting a carboxylic acid chloride of the general formula:- R R 3 5
R
N C C (CH 2 -O-(CH2) C COC1 (IV) R2 R R6
R
4 6 8 ‘I i -8- V in which R -R 8 m and n have the above-given meanings 1 8 and in which R1 can also be an acyl radical or, together with R 2 can also be a phthaloyl radical as protective group, with a trialkyl phosphite of the general formula:-
P(OR’)
3 (V) in which R’ is an alkyl radical containing up to 4 carbon atoms and preferably a methyl, ethyl, isopropyl or isobutyl radical, to give an acyl phosphonate of the general formula:- R R R R 0 0 R 3 5 7 1 I I i 1I N C C (CH 2 )m-0-(CH 2 C C P(OR’) 2
(VI)
SR
2 1 1 t R 4 R R in which R -Rg, m, n and R’ have the above-given meanings and R1 can also be an acyl radical or, together with R 2 can be a phthaloyl radical, subsequently reacting with a dialkyl phosphite of the general formula:- 0 i
(VII)
H-P(OR’)
2 in which R’ has the above-given meaning, to give a diphosphonate of the general formula:-
R
R 2
R
3 C
R
4 R5 R 7
P(OR’)
2 C (CH2)m-0-(CH 2 n C C OH I i i
R
6 R 8
P(OR’)
2 0 0
(VIII)
ii -:E i :i
I
,i i% C 1 n in which R -Rg, m, n and R’ have the above-given ‘meanings and R 1 can also be an acyl radical or, together with R2, can form a phthaloyl radical, optionally removing the phthaloyl radical by hydrazinolysis and saponifying the resultant tetraester to the corresponding diester or acid of general formula I, whereby, under these conditions, the acyl or phthaloyl radical used as protective group, is simultaneously split off; or c) when n is 0, reacting a compound of the general formula:- R R3 1 13 N C C (CH 2 OH (IX) R
I
2 R 4
R
6 20 in which R1-R 6 and m have the above-given meanings, with an epoxide of the general formula:- 0
I:
R 7 0 P(OR’) T, P (OR’ 2 8 H0
(X)
in which R 7
R
8 and R’ have the above-given meanings, and, if desired, saponifying the resultant I diphosphonic acid derivative of the general formula:- 0
!I’
R
3
R
5
R
7
P(OR’)
SN C C (CH 2 m 0 C C OH (XI)
R
2 2 R2 4
R
6
R
8 P(OR’)2 iii f 0 in which R 1
-R
8 R’ and m have the above-given meanings, to the corresponding diester or acid; or III. when X in general formula I is an -NR RI radical, reacting a carboxylic acid derivative of the general formula:- SR3 R5 R 7 1 115 N C C (CH 2 )m-0-(CH 2 C A (XII) 1 R2 2 R 4
R
6
R
8 in which R 1
-R
8 m and n have the above-given meanings and A is a nitrile, imino ether or -CONR 10
R
11 radical, 4 RI 0 and R. having the above-given meanings, with a phosphorus compound of the general formula:-
PT
3
(XIII)
in which T is a halogen atom, a hydroxyl group or an OR’ radical, R’ having the above-given mea,,ing, and i possibly saponifying; or ii– c- rr_- i -i i -11- IV. when X in general formula I is a hydrogen atom a) reacting a compound of the general formula:- R R3 ,N C C (CH 2 m U (XIV) 2 R R in which RI-R 6 and m have the above-given meanings and R1 can also be an acyl radical or, together with R 2 a phthaloyl radical and U is a reactive group, for example a halogen atom or a sulphonate group, with a diphosphonic acid derivative of the general formula;- 0
II
SR
7 P(OR’ 2 HO (CH 2 C C H (XV)
SR
8
P(OR’)
2 0 in which R7, R 8 R’ and n have the above-given meanings, optionally removing the phthaloyl radical by hydrazinolysis and optionally saponifying the tetraester formed to the corresponding diester or acid, whereby, under L these conditions, the acyl or phthaloyl radical used as protective group, is simultaneously split off; or b) adding a compound of the general formula:- R 3
RR
R1 3 R1 N C C (CH 2 OH (IX) 2 R 4
R
6 -12in which R 1
-R
6 and m have the above-given meanings, to a compound of the general formula:- 0 R P(OR’) C C
(XVI)
R
8
P(OR’)
2 8 2 0 in which R 7
R
8 and R’ have the above-given meanings, and optionally saponifying the tetraester obtained to the corresponding diester or acid; or c) reacting a compound of the general formula:- 1 T R 3 R R in which R 1
-R
8 U, m and n have the above-given meanings and R 1 can also be an acyl radical or, together with R 2 can be a phthaloyl radical, with a diphosphonic acid derivative of the general formula:l 20 P(OR’ )2 i H 2 C (XVIII)
P(OR’)
0 in which R’ has the above-given meaning, removing, if desired, the phthaloyl radical by hydrazinolysis and -13optionally saponifying the resultant tetraester to the corresponding diester or acid, whereby, under these conditions, the acyl or phthaloyl radical used as protective group is simultaneously split off; or d) when R 8 is a hydrogen atom, catalytically hydrogenating a compound of the general formula:- N C C (CH(CH 2 CH)- C C (XIX) R2 R R 6 P(OR9) 41 6 00 in which R 1
-R
7
R
9 m and n have the above-given meanings and R can also be an acyl radical; jand subsequently, if desired, saponifying the resultant Stetraester to the corresponding diester or acid, i 15 whereby acyl radicals possibly present can thereby also ~b h- split off at the same time and, if desired, converting a free acid obtained into a pharmacologically Sacceptable salt.
fi. In the case of the reductive alkylation (process a mixture of primary or secondary amines of general formula II and of a carbonyl compound or an acetal thereof is treated in the presence of a hydrogenation catalyst, for example palladium on charcoal or nickel, with hydrogen under atmospheric or elevated pressure or formic acid is used as reducing -14agent. Furthermore, the alkylation of a secondary amine df general formula I can be carried out especially advantageously by the phase transfer process with dialkyl sulphates.
The carboxylic acids of general formula II used i in process II a) are reacted with 1 2 and preferably with 1.5 mole of phosphorous acid or phosphoric acid and 1 to 2 and preferably 1.5 mole of phosphorus trihalide or phosphorus oxyhalide at a temperature of from 80 to 130 0 C. and preferably of from 100 to 1100C.
The reaction can also be carried out in the presence of a diluent, for example a halogenated hydrocarbon V and especially chlorobenzene, tetrachloroethane or also Ssulfolane or dioxan. The subsequent hydrolysis takes place by boiling with water but advantageously with semi-concentrated hydrochloric or hydrobromic acid.
As phosphorus trihalides in the above process, there can be used, for example, phosphorus trichloride or i phosphorus tribromide and, as phosphorus oxyhalide, 1 20 especially phosphorus oxychloride.
.In the case of process II the acid chloride U’ of general formula IV is reacted with the trialkyl phosphite of general formula V at a temperature of from 0 to 60 0 C. and preferably of from 20 to 40 0 C. It is possible to work without a solvent or also in the presence of an inert solvent, for example diethyl ether; tetrahydrofuran, dioxan or a halogenated hydrocarbon, for example methylene chloride. The acyl phosphonate of general formula VI obtained as intermediate can be isolated or further reacted directly. The subsequent reaction is carried out in the presence of a weak base, preferably of a secondary amine, for example dibutylamine, at a temperature of from 0 to 60 0 C. and preferably of from 10 to 30°C. When R and R 2 together form a phthaloyl radical as protective group, this is split off by hydrazinolysis or acid hydrolysis. In the case of hydrazinolysis, hydrazine is used in acetic acid or also in ethanol at a temperature of from 20 to 0 C. The acidic hydrolysis can be carried out very well by boiling with semi-concentrated hydrochloric acid. In this manner, an acyl radical, preferably an acetyl radical, used as protective group, is also split off.
In the case of process II the alcohols of general formula IX are, as a rule, used in the form of their alkali metal salts and preferably as their sodium salts. As solvent, it is preferred to use j toluene, dioxan, tetrahydrofuran or also dimethyl- ‘i formamide. The reaction is carried out at a temperature of from 20 to In the case of process III, the nitriles of general formula XII are reacted with phosphorous acid at a temperature of from 110 to 1800C. The reaction can be carried out with a solvent or in the presence -iI -16of an aprotic solvent, for example diethylene glycol dimethyl ether or diethylene glycol diethyl ether.
However, the nitriles can also be reacted with a phosphorus trihalide, for example phosphorus tribromide or phosphorus trichloride, in an inert solvent, for example dioxan or tetrahydrofuran, optionally with the addition of water, at a temperature of from 20 to 80 0
C.
Imino ethers of general formula XII can be reacted with dialkyl phosphites, preferably in the presence of equimolar amounts of sodium, in an inert solvent, for example diethyl ether, dioxan or also benzene, the reaction taking place, as a rule, at the reflux temperature of the solvent employed. Acid amides of general formula XII can be reacted in an inert solvent, for example a halogenated hydrocarbon or an ether, i such as diethyl ether, with a mixture of phosphorus pentahalide/phosphorous acid or also of oxalyl Schloride/trialkyl phosphite.
In the case of process IV the diphosphonic acid derivative of general formula XV is used in the form of a sodium or potassium salt. For this purpose, it is reacted with sodium, potassium or the corresponding hydride in an inert solvent, for example benzene, toluene or dimethylformamide, at a temperature of from 0 to 40 0 C. and preferably of about 25°C. The alkali metal salt is reacted, without isolation, with the appropriate halide or sulphonate, the temperature -17thereby used being from 20 to 1100C.
If R1 and R 2 together form a phthaloyl radical as protective group or R1 is an acyl radical and preferably an acetyl radical, these radicals are split off in the manner described in process II b).
In the case of process IV the alcohols of general formula IX are used in the form of their alkali metal salts and preferably of their sodium salts. For this purpose, they are reacted with sodium or sodium hydride in an inert solvent, for example benzene, toluene, dioxan or dimethylformamide, at a temperature of from 0 to 60 0 C. and preferably of about 250C. As a rule, the alkali metal salt is reacted, without isolation, with the appropriate diphosphonate of ij general formula XVI, the temperature used being from to 800C.
In the case of process IV the methylene- Sdiphosphonic acid esters of general formula XVIII are used in the form of their sodium or potassium salts.
For this purpose, they are reacted with sodium, Spotassium or the corresponding hydride in an inert solvent, for example benzene, toluene or dimethyl- C formamide, at a temperature of from 0 to 400C. and preferably of about 250C. The alkali metal salt is reacted, without isolation, with the appropriate halide or sulphonate, the temperature used being from 20 to 1100C.
-18- The hydrogenation in the case of process IV d) is carried out in the presence of a noble metal catalyst, for example palladium on charcoal or platinum, in an alcohol, for example methanol or ethanol, as solvent or also in water. However, nickel can also be used in an alkaline medium. The splitting off of the N-acyl radical can be carried out under alkaline conditions but preferably under acidic conditions, for example with 6N hydrochloric acid.
Optically-active compounds of general formula I are usually prepared by using optically-active starting materials.
The aminooxaalkanecarboxylic acids used in process II a) are usually prepared in the following 15 manner: The appropriate aminoalkanol is reacted with, for example, a haloacetic acid ester, to give an aminooxaalkanecarboxylic acid ester which, depending upon Sthe chain length and the substitution on the nitrogen 1 atom, can be cyclised to give an oxalactam. The resultant carboxylic acid ester is saponified in the usual manner under acidic or alkaline conditions. In the case of ring formation, the lactam ring is opened by boiling with barium hydroxide solution and the barium salt of the aminooxaalkanecarboxylic acid is converted into the free acid with sulphuric acid.
The aminoalkanols used in the case of this process, as well as in the case of processes II c) and -19- IV are, as a rule, known from the literature or can easily be prepared from the appropriate amino acids or the esters thereof by reduction with, for example lithium aluminium hydride.
The aminooxaalkanecarboxylic acid nitriles or amides used in the case of process III can be synthesised from the appropriate aminoalkanols by reaction with haloacetic acid nitriles or haloacetic acid amides. From the nitriles thus obtained can be obtained the corresponding imino ethers by conventional processes, for example by reaction with a lower alcohol i in the presence of gaseous hydrogen chloride.
By the reaction of an aminoalkanol with a phosphorus halide, for example phosphorus trichloride or phosphorus tribromide, or with an aliphatic or aromatic sulphochloride, for example methanesulpho- SIchloride or benzenesulphochloride, there is obtained i a compound of general formula XIV used in the case of process IV a).
The compounds of general formula XIX used in the case of process IV b) can be prepared, for example, by i the elimination of an H-Y group, wherein Y is, for example, a halogen atom, preferably a bromine or chlorine atom, or an acyloxy radical, especially an acetoxy or propionyloxy radical. The elimination can take place by the use of bases, for example tertiary amines and especially triethylamine, pyridine or
A
diazabicycloundecane, in an inert solvent, for example an alcohol or ether, such as dioxan or tetrahydrofuran.
In the case of the splitting off of acetic or propionic acid, there is preferably used the tetrasodium or tetrapotassium salt of the corresponding diphosphonic acid, the splitting off being carried out V by heating to a temperature of from 180 to 300 0 C. and preferably of from 180 to 240 0 C. The free acid can be liberated from the tetraalkali metal salt, for example by treatment with an acidic ion exchanger, such as Amberlite IR 120, H1 form.
The above-mentioned starting compounds can be used as racemates or as enantiomers, the opticallyactive compounds usually being obtained from the corresponding optically-active amino acids.
The tetraalkyl esters possibly obtained in the case of the above-mentioned processes can be saponified to the diesters or to the free tetraacids. The saponification to diesters takes place, as a rule, by treating the tetraalkyl esters with an alkali metal halide, preferably with sodium iodide, in an appropriate solvent, for example acetone, at ambient temperature.
4 t There is thereby formed the symmetrical diester/ disodium salt which can possibly be converted into the diester/diacid by means of an acidic ion exchanger.
The saponification to the free diphosphonic acids takes place, as a rule, by boiling with semi-concentrated -21hydrochloric or hydrobromic acid. However, a splitting off can also be carried out with a trimethylsilyl halide and preferably with the bromide or iodide. On the other hand, the free diphosphonic acids can again be converted into the tetraalkyl esters by boiling with orthoformic acid alkyl esters. The free diphosphonic acids of general formula I can be isolated as free acids or in the form of their mono- or dialkali metal salts. As a rule, the alkali metal salts can be purified by reprecipitation from water/methanol or water/acetone.
l As pharmacologically acceptable salts, there are I especially used the alkali metal and ammonium salts which are prepared in the usual manner, for example by titration of the compounds with inorganic or organic bases, for example sodium or potassium hydrogen SIcarbonate, aqueous sodium hydroxide solution, aqueous potassium hydroxide solution, aqueous ammonia solution or amines, for example trimethylamine or triethylamine.
20 The new compounds of general formula I according to the present invention and the salts thereof can be I administered enterally or parenterally in liquid or solid form. For this purpose, there can be used all conventional forms of administration, for example tablets, capsules, dragees, syrups, solutions, suspensions and the like. As injection medium, it is preferred to use water which contains the additives V -22- :I usual in the case of injection solutions, for example stabilising agents, solubilising agents and buffers.
I Additives of this kind include, for example, tartrate I and citrate buffers, ethanol, complex formers (such as ethylenediamine-tetraacetic acid and the non-toxic salts thereof) and high molecular weight polymers (such as liquid polyethylene oxide) for viscosity regulation.
Liquid carrier materials for injection solutions must be sterile and are preferably filled into ampoules.
j 10 Solid carrier materials include, for example, starch, lactose, mannitol, methylcellulose, talc, highly dispersed silicic acid, high molecular weight fatty acids (such as stearic acid), gelatine, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats and solid high molecular weight polymers (such as polyethylene glycols). Compositions suitable for oral administration can, if desired, contain flavouring and 1 i sweetening agents.
The dosage used can depend upon various factors, for example mode of administration, species, age and/or the individual state of health. The doses to be administered daily are from about 0.1 to 100 mg./human and preferably 1 to 20 mg./human and can be administered divided up one or more times.
Preferred in the sense of the present invention t< are, apart from the compounds described in the following Examples and compounds which can be derived by the -23combination of all of the definitions given in the *1claims, the following diphosphonates, as well as the sodium salts and the methyl, ethyl and isopropyl esters j thereof: 5-N,N-dimethylamino-3-oxapentane-l-hydroxy-l,l- I diphosphonic acid 5-N-methyl-N-propylamino-3-oxapentane-l-hydroxy-1,ldiphosphonic acid 5-N-methyl-N-nonylamino-3-oxapentane-l-hydroxy-1,1diphosphonic acid 5-N-benzylamino-3-oxapentane-l-hydroxy-l,l-diphosphonic acid I 5-N-isobutyl-N-methylamino-3-oxapentane-l-hydroxy-1,ldiphosphonic acid 5-N-methallyl-N-methylamino-3-oxapentane-l-hydroxy- 1 ,1-diphosphonic acid (2-methoxyethyl )-N-methylamino-3-oxapentane-lhydroxy-l ,l-diphosphonic acid 5-N-(2-hydroxyethyl)-N-methylamino-3-oxapentane-lhydroxy-l,l-diphosphonic acid 2 ~iL S-N-(2-methylthioethyl)-N-methylamino-3-oxapentane-lhydroxy-l -diphosphonic acid 5-N-(4-methylbenzyl)-amino-3-oxapentane-l-hydroxy-l,1diphosphonic acid 5-N-(2-chlorobenzyl)-amino-3-oxapentane-l-hydroxy-l,ldiphosphonic acid 3-oxapentane- 1-hydroxy- 1,1-diphosphonic acid -24- 5-amino-7-methyl-3-oxaoctane-1-hydroxy-1 .1diphosphonic acid 5-amino-6-phenyl-3-oxahexane-l-hydroxy-.,1diphosphonic acid 5-amino-6-(3-indoJlyl)-3-oxahexane-J.-hydroxy-1,1diphosphonic acid 5-amino-6-(4-imidazolyl)-3-oxahexane-.-hydroxy-1,1diphosphonic, acid 5-amino-6-hydroxy-3-oxahexane-1-hydroxy-1,1diphosphonic acid 5-amino-7-methylthio-3-oxaheptane-l-hydroxy-1,.diphosphonic acid 5-N-methyl-N-propylamino-3-oxahexane-l-hydroxy-. 4diphosphonic acid 5-N-methyl-N--pentylamino-3-oxahexane-l-hydroxy-.,1diphosphonic acid 5-N-allyl-N-methylamino-3-oxahexane-1-hydroxy-1,1diphosphonic acid 5-amino-6- (4-hydroxyphenyl )-3-oxahexane---hydroxy- 1,1-diphosphonic acid ~ff 5-amino-4,4-dimethyl-3-oxapentane-1-hydroxy-1,4diphosphonic acid 5-amino-4-phenyl-3-oxapentane-l-hydroxy-1,1diphosphonic acid 5-amino-2-methyl-3-oxapentane-1.-hydroxy-1,1diphosphonic acid 5-amino-2, 2-dimethyl-3-oxapentane-1--hydroxy-1 ,1diphosphonic acid II# It I II 4, I I t II 4 I 4 41 5-amino-2-phenyl-3-oxapentane-1-hydroxy-1 ,1diphosphonic acid (l-pyrrolidinyl )-3-oxapervtane-l-hydroxy-1 ,1diphosphonic acid 5-(l-piperidinyl)-3-oxapentane-1-hydroxy-1,1diphosphonic acid (3-hyd-roxy- 1-pyrrolidinyl -3-oxapervtane- 1-hydroxy- 1,1diphosphonic acid (3 ,4-dimethoxy-l-pyrrolidinyl )-3-oxapentane-1-hydroxy- 1,1-diphosphonic acid 3-dihydroisoindolin-1-yl)-3-oxapentane-l-hydroxy- 1,1-diphosphonic acid (octahydroisoindolin-1-y1)-3-oxapentane-l-hydroxy- 1 ,1-diphosphonic acid 15 5-(decahyd-oquinolin-1-yl)-3-oxapentane-1-hydroxy-1,1diphosphonic acid 5-(l-pipe-razinyl)-3-oxapentane-l-hydroxy-1,1diphosphonic acid 5-(4-methyl-l-piperazinyl)-3-oxapentane-l-hydroxy-1,1diphosphonic acid thiamorpholinyl -3-oxapentane- 1-hydroxy- 1,1diphosphonic acid 5- (4-hydroxy-l-piperidinyl)-3-oxahexane-l-hydroxy- 1,1-diphosphonic acid S-4-(2-pyrrolidinyl)-3-oxabutane-l-hydroxy-1,1diphosphonic acid 4- (2-pipe-idinyl)-3-oxabutane-1-hydroxy-1, 1diphosphonic acid I -26- 4- (l-methyl-2-piperidinyl.) -3-oxabutane-l-hydroxy- 1,1-diphosphonic acid 5-(1-methyl-2-piperidinyl)-3-oxapentane-l-hydroxy- 1,1-diphosphonic acid 4-(octahydroindolin-2-yl)-3-oxabutane-1-hydroxy-1,1- U diphosphonic acid 4-(l-ethyl-2-pyrrolidinyl)-3-oxabutane-l-hydroxy-1,1diphosphonic acid 3-(3-pyrrolidinyl)-3-oxapropane-1-hydroxy-1,1diphosphonic acid 5-amino-5,5--butylene-3-oxapentane-1-hydroxy-1,1diphosphonic acid ,N-dimethylamino- 5, 5-pentylene- 3-oxapentane- 1hydroxy-1,1-diphosphonic acid 4-(2-aminocyclohexyl)-3-oxabutane-1-hydroxy-1,1diphosphonic acid 3-(2-aminocyclopentyl)-3-oxapropane-l-hydroxy-1,1diphosphonic acid 4-(2-aminocyclopentyl)-3-oxabutane-l-hydroxy-1,1diphosphonic acid 4- (2-N ,N-dimethylarninocyclohexyl )-3-oxabutane-lhydroxy-1,1-diphosphonic acid 5-amino-4 ,4-butylene- 3-oxapentane- 1-hydroxy- 1, 1diphosphonic acid 6-amino-2,2-butylene-3-oxahexane-1-hydroxy-1,1diphosphonic acid 5-N,N-dimethylamino-2 ,2-pentylene-3-oxapentane-1hydroxy-1 ,1-diphosphonic acid -27- 1 ,5-diamino-3-oxapentane-1 ,1-diphosphonic acid 5-amin9-1-N,N-diethylamino-3-oxahexane-1 ,1diphosphonic acid 3-oxahexane-1 ,1-diphosphonic acid R-5-amino-3-oxahexane-1 ,1-diphosphonic acid S-5-arnino-3-oxahexane-1,1-diphosphonic acid 5-N,N-dimethylamino-3-oxapentane-1 ,1-diphosphonic acid R-5-amino-7-methyl-3-oxaoctane-l-hydroxy-1,1diphosphonic acid R-5-amino-6-phenyl-3-oxahexane-l-hydroxy-1,1diphosphonic acid S-5-amino-6-phenyl-3-oxahexane-l-hydroxy-1 ,1diphosphonic acid R-5-amino-6-(3-indoly1)-3-oxahexane-1-hydroxy-1,1diphosphonic acid S-5-amino-6-(3-indolyl)-3-oxahexane-1-hydroxy-1,1diphosphonic acid R-5-amino-6- (4-imidazolyl )-3-oxahexane-l-hydroxy-1 ,1- 0 diphosphonic acid 120 S-5-amino-6-(4-imidazolyl)-3-oxahexane-l-hydroxy-1,1diphosphonic acid i~j 0.:.R-5-amino-1 ,6-dihydroxy-3-oxahexane-1 ,1-diphosphonic 0 acid S- 5-amino-i, 6-dihydroxy- 3-oxahexane- 1, 1-diphosphonic C II 25 acid R-5-amino-7-methylthio-3-oxaheptane-1-hydroxy-1 ,1diphosphonic acid -28- S-5-amino-7-methylthio-3-oxaheptane-l-hydroxy-1,4diphosphonic acid R-5-N-methyl-N-propylarnino-3-oxahexane-l-hydroxy-1 ,1diphosphonic acid S-5-N-methyl-N-propylamino-3-oxahexane-l-hydroxy-1,1diphosphonic acid R-5-N-methyl-N-pentylamino-3-oxahexane-l-hydroxy-1,1diphosphonic acid S-5-N-methyl-N--pentylamino-3-oxahexane-l-hydroxy-1 ,1diphosphonic acid R-5-N-allyl-N-methylamino-3-oxahexane- 1-hydroxy-1 ,1diphosphonic acid S-5-N-allyl-N-methylamino-3-oxahexane-l-hydroxy-1,1diphosphonic acid R-5-amino-5-6-(4-hydroxyphenyl)-3-oxahexane-l-hydroxy- 1,1-diphosphonic acid S-5-amino--6-(4-hydroxyphenyl)-3-oxahexane-l-hydroxy- 11 ,1-diphosphonic acid R-5-amino-4-phenyl-3-oxapentane-l-hydroxy-1,1diphosphonic acid S-5-amino-4-phenyl-3-oxapentane-l-hydroxy-1 ,1diphosphonic acid R-5-amino-2-methyl-3-oxapentane-1-hydroxy-1 ,1diphosphonic acid S-5-amino-2-methyl-3-oxaheptane-1-hydroxy-1 ,1diphosphonic acid R-5-amino-2-phenyl-3-oxapentane-l-hydroxy-1 ,1diphosphonic acid i- -29- S-5-amino-2-phenyl-3-oxapentane-l-hydroxy-l,1diphosphonic acid 5-amino-2-methyl-3-oxahexane-l-hydroxy-l,1-diphosphonic acid 6-amino-3-oxaheptane-l-hydroxy-l,1-diphosphonic acid 6-amino-5-methyl-3-oxahexane-l-hydroxy-l,1-diphosphonic acid 6-amino-4-methyl-3-oxahexane-l-hydroxy-l,1-diphosphonic acid. The following Examples show some of the process Ivariants which can be used for the synthesis of the Scompounds according to the present invention. However, they are not to represent a limitation of the subject Sh matter of the present invention. As a rule, the compounds are obtained as high melting point solid products (mono- or disodium salts), the structures of which have been verified by H, P and possibly by C NMR spectroscopy. The purity of the substances was determined by means of C, H, N, P, S and Na analyses, as well as by thin layer electrophoresis (cellulose, oxalate buffer of pH For the characterisation of the individual compounds, there are given the Mrel values (relative mobility), referred to pyrophosphate (Mre Example 1. R,S-5-Amino-3-oxahexane-l-hydroxy-l,1-diphosphonic acid. 0.67 g. (5 mmol) R,S-5-amino-3-oxahexanoic acid are melted at 100 0 C. with 0.82 g. (10 mmol) phosphorous A acid. The oil bath used is removed, 1 ml. (11 mmol) phosphorus trichloride is added dropwise thereto and heating continued for a further 24 hours at an external temperature of 100 0 C. After cooling, the reaction mixture is mixed with 10 ml. water, boiled under reflux for 45 minutes and filtered off with suction. The filtrate is concentrated to one half, the solution is adjusted to pH 5 with 10N aqueous sodium hydroxide solution, mixed with 20 ml. methanol and the solution is cooled in an ice-bath. The precipitate obtained is filtered off with suction, washed with methanol and dried. The residue is dissolved in a little water and purified over an ion exchanger column (35 g. Amberlite-IT 120; H form). There is obtained 0.49 g. (34% of theory) of the I desired compound which contains 0.5 mole of water of crystallisation; m.p. 240 260 0 Mrel 0.40. The R,S-5-amino-3-oxahexanoic acid used as starting material is prepared in the following way: R,S-5-methylmorpholin-3-one 62 64°C.) is boiled with barium hydroxide and the free acid produced from the barium salt with sulphuric acid at pH 5; m.p. 190 193°C. In an analogous manner, by reacting phosphorous acid and phosphorus trichloride with the following starting material, there is obtained: a) from R,S-5-N,N-dimethylamino-3-oxahexanoic acid I -31- 108 110'C.) (prepared by the reductive methylation of R,S-5-amino-3-oxahexanoic acid by means of formic acid/formaldehyde), R,S-5.-N,N-dimethylamino-3oxahexane-l-hydroxy-1,1-diphosphonic acid as the free acid with 1 mole of water of crystallisation in a yield of 36% of theory; m.p. about 270'C. M rel 0.40. Example 2. Analogously to Example 1, there are obtained, by the use of: a) 5-amino-3-oxapentanoic acid 188 190'C.), 5-amino-3-oxapentane-l-hydroxy-1,1-diphosphonic acid with 1 mole water of crystallisation; yield 31% of theory; 255 26000.; M rel :0.30. b) 6-(N--acetylamino)-3-oxahexanoic acid (oil), 6-amino- 3-oxahexane-l-hydroxy-1,1-diphosphonic acid with 1 mole water of crystallisation; yield 23% of theory; m.p. 125 130'C.; M rel: 0.30. c) 5-N-methylamino-3-oxapencanoic acid 242 245'C.), 5-N-methylamino-3-oxapentane-l-hydroxy-1,1diphosphonic acii with 1 mole water of crystallisation; yield 28% of theory; m.p. 155 160'C.; Mrl:0.35. d) 6-N,N-dimethylamino-3-oxahexanoic acid hydrochloride (oil), 6-N,N-dimethylamino-3-oxahexane-l-hydroxy- 1,1-diphosphonic acid with 1 mole water of crystallisation; yield 22% of theory; m.p. 115 120'C.; M 1 e: 0.30. 00 0 a 00 0@ o 0 00 o0 *a a 0 0000a -32- V e) R-5-amirio-3-oxahexanoic acid 182 -185'C.; -30.50. c =1.5 in water), R-5-amino-3oxahexane-l-hydroxy-l .3-diphosphonic acid with 1 mole water of crystallisation; yield 30%~ of theory; m.p. 138 12300.; [oJD c= 0.8 in water; MA 1 0.30. f) S-5-amino--3-oxahexanoic acid 180 18200.; 1"D 28.5', c =1.4 in water), S-5-amino-3oxahexane-l-hydroxy-1 ,l-diphosphonic acid with 1 mole water of crystallisation; yield 34%~ of theory; m.p. 115 120'C.; [D~ 0 +21.20, c 0.8 in water; M 1 e: 0.30. 91g) 5-amino-6-methyl-3-oxaheptanoic acid (oil), 6-methyl-3-oxaheptane-l-hydroxy-1,1-diphosphonic 15 acid with 1 mole water of crystallisation; yield 4$ h) S-5-arnino-6-methyl-3--oxaheptanoic acid 140- 14500.; [a]1 +23.90, c =1 in water), 6-methyl-3-oxaheptane-l-hydroxy-1,1-diphosphonic acid with 1 mole water of crystallisation; yield 20 27%~ of theory; m.p. 245 25000.; EID +19.30, c 1.0 in water; M 1 e: 0,.30. i) R-5-amino-6-methyl-3-oxaheptanoic acid 143 14700.; [a] 20 c 1.1 in water), 6-methyl-3-oxaheptane-l-hydroxy-1,1-diphosphonic acid with 1 mole water of crystallisation; yield 26%~ of theory; m.p. 245 25000.; ILICD c in water; M Nl 0.30. -33jS-5-amino-7-methyl-3-oxaoctanoic acid; m.p. 148.- 150 0 20 c =1.2 in water), S-5-amino-7-methyl-3-oxaoctane-1-hydroxy-1,4diphosphonic acid with 1 mole water of crystallisation; yield 31% of theory; m.p. 250 255 0 C.; D 😀 14.80, c 1.2 in water; M re: 0.30. k) 5-amino-5-methyl-3-oxahexanoic acid 243 4 245'C. 5-amino-5-methyl-3-oxahexane-1-hydroxy-1,1diphosphonic acid with 1 mole water of crystallisation; yield 27% of theory; m.p. 155 -160'C.; flM re:0.40. 1) 5-amino-4-methyl-3-oxapentanoic acid 213 215'C.), 5-amino-4-methyl-3-oxapentane-l-hydroxy- 1,1-diphosphonic acid with 1 mole water of crystallisation; yield 33% of theory; m.p. 145- 150 0 M 1 :el 0.30. m) 5-(4-miorpholinyl)-3-oxapentanoic acid hydrochloride (oil), 1-hydroxy-5-(4-morpholinyl)-3-oxapentane-1,1diphos phonic acid with 1 mole water of crystallisation; yield 28% of theory; m.p. 135 140'C.; N 1 0.35. n) 3-(N-acetyl-3-piperidinyl)-3-oxapropionic acid (oil), 1-hydroxy- (3-piperidinyl )-3-oxapropane- 1diphosphonic acid with 1 mole water of crystallisation; yield 15% of theory; m.p. 185 190 0 C.; M rej 0.30. -34o) 3-(2-aminocyclohexyl)-3-oxapropionic acid (m.p. 218- 220-C.), 3-(2-aminocyclohexyl)-3-oxapropane- 1-hydroxy-1,l-diphosphonic acid with 1 mole water of crystallisation; yield 19% of theory; rn.p. 215 2200C.; MA 1 0.25. p) 5-amino-4,4-pentylene-3-oxapentanoic acid (m.p. 203 20500.), 5-amino-4,4-pentylene-3-oxapentane- 1-hydroxy-l,1-diphosphonic acid with 1 mole water of crystallisation; yield 29% of theory; m.p. 235- 240'C. Mre 0.30. q) S-4-(2-pyrrolidinyl)-3-oxabutyric acid 152 1550C.; [a]D +20.30, c 1.3 in water, S-1- ID diphosphonic acid with 1 mole water of crystallis- 15 ation; yield 26% of theory; m.p. 120 125 0 C., 0.9 in water; M 030 r) R-5-amino-4-methyl-3-oxapentanoic acid 210- 21200.; [CJd c 1 in water), 4-methyl-3-oxapentane-l-hydroxy-1,1-diphosphonic acid with I mole water of crystallisation; yield 23% of 200 theory; m.p. 140 145 0 [a]D c 1 in water; M 1 e: 0.30. s) S-5-amino-4-methyl-3-oxapentanoic acid 212 21400.; [I 20 D +97.80, c =1 in water), S-S-amino- 4-methyl-3-oxapentane-l-hydroxy-1,1-diphosphonic acid with 1 mole water of crystallisation; yield of theory; m.p. 145 15000.; 20 +22.90, c 1 in water, M rel: 0.30. t) 4-(2-piperidinyl)-3-oxabutyric acid 158 1609C.), l-hydroxy-4-(2-piperidinyl)-3-oxabutane- 1,1-diphosphonic acid with 1 mole water of crystallisation; yield 24% of theory; m.p. 175 I 5 180 0 Mre 0.30. rel The 5-amino-3-oxapentanoic acid used in Example 2 a) is prepared in the following way: Ethanolamine is reacted in the presence of sodium hydride with ethyl chloroacetate to give morpholin-3-one 100 102 0 and the desired acid obtained therefrom by heating with barium hydroxide and subsequent t i treatment with sulphuric acid. i The intermediate products set out in the following Table are prepared and reacted in an analogous manner: i 'i -I sI -36- 11 ii Example Morpholinone M.P. 00. [a]D2 in No. methanol 2 c N-methylmorpholin- 3-one oil 2 e R-5-methylmorpholin-3-one 60-62-37 2 f S-5-methylmorpholin-3-one 59-61 +3.10 2 g 5-isopropylmorpholin-3-one 86-88 2 h S-5-isopropylmorpholin-3-one 86-88 +3.90 2 i R-5-isobutylmorpholin-3-one 87-89-43 2 j S-5-isobutylmorpholin-3-one 70-72-40 2 k 5,5-dimethylmorpholin-3-one 133-35 *2 1 6-methylmo-rpholin-3-one 96-98- 2 o 2-oxa-5-azabicyclo[4.4.0]- 174-76decan-4-one 2 p l-oxa-4-azabicyclospiro- 93-95- 5]undecan-3-one 2 q S-3-oxa-6-azabicyclo[4.3.0]- 64-66nonan- *2 r R-6-methylmorpholin-3-one 96-98 -134.10 2 s S-6-methylmorpholin-3-one 95-97 +131.10 I2 t 3-oxa-6-azabicyclo[4.4.0]- oil- In the case of Examples 2 b) and 2 the starting aminoalcohols are first acetylated on the nitrogen atom, subsequently reacted in the presence of sodium I- -37hydride with ethyl bromoacetate to give the corresponding ethyl alkoxyacetate and then saponified with an aqueous solution of sodium hydroxide. All the intermediates are obtained in the form of an oil. In the case of Examples 2 d) and 2 the tert.-aminoalcohols are reacted in the presence of sodium hydride with ethyl bromoacetate (2 or with the sodium salt of chloroacetic acid (2 in the latter case esterified with ethanol-sulphuric acid to the corresponding ethyl ester and in both cases subse- Squently saponified with 2N hydrochloric acid. Here, too, all the intermediates are obtained in the form of an oil. Example 3. 15 5-Amino-3-oxapentane-l,1-diphosphonic acid. 1.73 g. (6 mmol) Methanediphosphonic acid tetraethyl ester is added dropwise to 144 mg. (6 mmol) sodium hydride in 5 ml. anhydrous toluene. After completion of the evolution of hydrogen, stirring is continued for 30 minutes and then 1.7 g. (6 mmol) N-(2bromoethoxyethyl)-phthalimide 83 85 0 is added dropwise thereto. The reaction mixture is stirred for 24 hours at ambient temperature, then mixed with water, the aqueous phase is adjusted to pH 5 with 2N hydrochloric acid and the organic phase is separated off, dried and evaporated. The residue is purified over 250 g. silica gel (elution agent: methylene -38chloride/methanol 4/1 v/v) to give 0.35 g. (12% of theory)' 5-phthalimido-3-oxapentane-l,1-diphosphonic acid tetraethyl ester in the form of an oily substance. The ester is subsequently boiled under reflux for 12 hours with 10 ml. 6N hydrochloric acid and, after cooling, the precipitated phthalic acid is filtered off with suction. The residue is taken up in water, the solution is adjusted with 2N aqueous sodium hydroxide solution to pH 5 and mixed, while cooling with ice, with a large excess of methanol. The precipitate obtained is filtered off with suction and dried. There is obtained 0.125 g. of theory) of the desired compound in the form of the monosodium salt containing 1 mole water of crystallisation; S 15 m.p. 3000C.; M rel 0.30. t e l I a a Claims (8) 1. Compounds of the general formula:- 0 II R 1 R 3 R 5 R 7 P(OR 9 2 N C C (CH 2 n C C X (I) R R 6 R 8 P(OR 9 2 0 wherein R 1 and R 2 independently of one another, are hydrogen atoms, straight-chained or branched, saturated or unsaturated alkyl chains containing up to 9 carbon atoms which can optionally be substituted by bydroxyl, or C1-C5-alkylthio, a phenyl or C5-C7- cycloalkyl ring, whereby the phenyl ring can be option- ally substituted by C 1 -C 5 -alkyl, C 1 -C 5 -alkoxy, hydroxyl I D° 15 or halogen, or are C -C 7 -cycloalkyl or phenyl radicals, i' R 3 is a hydrogen atom, a straight-chained or branched o CI-C-alkyl radical which can optionally be substituted S 0 0o' 6 by hydroxyl, C 1 -C 5 -alkoxy, C 1 -C 5 -alkylthio, mercapto, phenyl, 3-indolyl or 4-imidazolyl, or a phenyl radical optionally substituted by hydroxyl or C 1 -C 5 -alkoxy, R R 6 R 8 and R 9 independently of one another, are hydrogen atoms or C 1 -C 5 -alkyl radicals, R 5 and R 7 independently of one another, are hydrogen atoms, 0 4 C 1 -C 5 -alkyl radicals or phenyl radicals optionally 0 25 substituted by hydroxyl or C1-C5-alkoxy, X is a hydrogen atom, a hydroxyl group or an -NR 10 R 11 radical, whereby dm m riiir and R 1 1 independently of one another, are hydrogen atoms or C 1 -C 5 -alkyl radicals and m and n are 0 or 1, whereby R 1 and R 2 together with the nitrogen atom to which they are attached, can form a mono- or bicyclic ring system containing 4 to 9 carbon atoms which is partly or wholly hydrogenated and possibly substituted by hydroxyl, C 1 -C 5 -alkyl or C 1 -C 5 -alkoxy and/or, in the case of a monocyclic ring, can be interrupted by an oxygen, nitrogen or sulphur atom, R1 and R 3 together with the carbon and nitrogen atoms to which they are attached, can form a five- or six-membered ring which can possibly be condensed with a further six-membered ring, R 1 and R 5 together with the carbon and nitrogen atoms to which they are attached, as well as the carbon 15 atom lying therebetween,can form a five- or six- membered ring, R 3 and R 4 together with the carbon atom to which they are attached, can form a five- or six- membered ring, R 4 and R 6 together with the carbon atoms to which they are attached, can form a five- or six-membered ring, R 5 and R 6 together with the carbon atom to which they are attached, can form a five- or six-membered ring and R 7 and R 8 together with the carbon atom to which they are attached, can form a five- or six-membered ring; as well as the pharmaco- logically acceptable salts thereof and the optical isomers thereof; with the proviso that R 1 and R 2 together with the nitrogen atom cannot form a piperidine or piperazine ring and R 1 and R 3 as well as R 1 and R together with the nitrogen atom cannot form a piperidine tA\ ring. -7 40 a 2. Compounds according to claim 1 wherein R1 is hydrogen or methyl, R 2 is hydrogen or methyl, R 3 is hydrogen or C 1 -C 5 alkyl, R 4 is hydrogen or methyl, R 5 is hydrogen or methyl, R 6 is hydrogen, R 7 is hydrogen, R 8 is hydrogen, R 9 is hydrogen, m is zero or 1, n is zero and X is a hydroxyl group whereby R 1 and R 6 together with the nitrogen atom form a morpholine ring, R 1 and R 3 together with the carbon and nitrogen atoms to which they are attached form of pyrrolidine ring, R 4 and Rg together with the carbon atom to which they are attached form a cyclohexyl ring and R5 and R 6 together with the carbon atom to which they are attached form a spiro-cyclopentane ring. I I'. fl o -41- 3. Process for the preparation of compounds of the general formula:- 0 R R3 R 5 R7 P(OR9 )2 N C C (CH )m-0-(CH 2 C C X (I) 2 m 2 n R R R R P(OR9) 0 wherein R 1 and R 2 independently of one another, are hydrogen atoms, straight-chained or branched, saturated i 10 or unsaturated alkyl chains containing up to 9 carbon atoms which can optionally be substituted by hydroxyl, or C -C -alkylthio, a phenyl or C5-C 7 cycloalkyl ring, whereby the phenyl ring can be option- i ally substituted by C 1 -C 5 -alkyl, C 1 -C 5 -alkoxy, hydroxyl or halogen, or are C- C 7 -cycloalkyl or phenyl radicals, R 3 is a hydrogen atom, a straight-chained or branched 1 C 1 -C 5 -alkyl radical which can optionally be substituted by hydroxyl, C 1 -C 5 -alkoxy, C 1 -C 5 -alkylthio, mercapto, phenyl, 3-indolyl or 4-imidazolyl, or a phenyl radical f/ 20 optionally substituted by hydroxyl or C 1 R R R 8 and R 9 independently of one another, are hydrogen atoms or C 1 -C 5 -alkyl radicals, R 5 and R 7 independently of one another, are hydrogen atoms, C 1 -C 5 -alkyl radicals or phenyl radicals optionally substituted by hydroxyl or C 1 -C 5 -alkoxy, X is a hydrogen atom, a hydroxyl group or an -NR 1 0 R 11 radical, whereby r I i r -42- RI0 and R 11 independently of one another, are hydrogen atoms dr Ci-C-alkyl radicals and m and n are 0 or 1, whereby R 1 and R 2 together with the nitrogen atom to which they are attached, can form a mono- or bicyclic ring system containing 4 to 9 carbon atoms which is partly or wholly hydrogenated and possibly substituted by hydroxyl, C1-C 5 -alkyl or C 1 -C 5 -alkoxy and/or, in the case of a monocyclic ring, can'be interrupted by an oxygen, nitrogen or sulphur atom, R 1 and R 3 together with the carbon and nitrogen atoms to which they are i 1attached, can form a five- or six-membered ring which V! can possibly be condensed with a further six-membered i ring, R 1 and R 5 together with the carbon and nitrogen atoms to which they are attached, as well as the carbon atom lying therebetween, can form a five- or six- membered.ring, R 3 and R 4 together with the carbon atom to which they are attached, can form a five- or six- membered ring, R 3 and R 6 together with the carbon atoms to which they are attached, can form a five- or six- membered ring, R 5 and R 6 together with the carbon atom to which they are attached, can form a five- or six- membered ring and R7 and R, together with the carbon atom to which they are attached, can form a five- or six-membered ring; as well as the pharmacologically acceptable salts thereof and the optical isomers thereof, wherein I. a compound of the general formula:- -43- 0 I R R 3 R 5 R P(OR 9 2 SN C C (CH 2 )m-0-(CH 2 C C X (II) H m R 4 R 6 R 8 P(OR 9 2 0 in which R R 3 -R 9 X, m and n have the above-given meanings, is mono- or dialkylated and the tetraester obtained optionally saponified to the corresponding diester or acid of general formula I; or II. when X in general formula I is a hydroxyl group a) a carboxylic acid of the general formula:- R R R R 1 R3 5 R7 'N C C (CH2)m-O-(CH 2 C COOH (III) R2 R R R 8 in which R 1 -Rg, m and n have the above-given meanings, is reacted with a mixture of phosphorous acid or phosphoric acid and a phosphorus halide or phosphorus oxyhalide and subsequently saponified to give the free diphosphonic acid; or b) a carboxylic acid chloride of the general formula:- R1 R 3 R5 R7 N C C (CH 2 )m-O-(CH 2 C COC1 (IV) S. I R, R 2 R 4 R 6 R 8 -44- in which R -R 8 m and n have the above-given meanings and Rl 1 can also be an acyl radical or, together with R2 can represent a phthaloyl radical as protective group, is reacted with a trialkyl phosphite of the general formula:- P(OR') 3 (V) Sin which R' is an alkyl radical containing up to 4 carbon atoms, to give an acyl phosphonate of the i i general formula:- R 3 R R 0 0 R I li II SN C C (CH 2 -0-(CH 2 C C P(OR') 2 (VI) iR I m n 2 i 2 \R S R4 R 6 R 8 in which R 1 -R 8 m, n and R' have the above-given i meanings and R1 can also be an acyl radical or, together with R 2 can represent a phthaloyl radical, subsequently reacted with a dialkyl phosphite of the general formula:- 0 S-P(VII), H-P(OR') 2 in which R' has the above-given meaning, to give a diphosphonate of the general formula:- 0 3 5 R7 P(OR')2 2N C- C (CH2)m (CH2)n C C OH (VIII) R 4 R 6 R 8 P(OR') 2 Ii iiZLiY"- ll l-u--rs;i-I -ir in which R 1 -R 8 m, n and R' have the above-given meanings, and R1 can also be an acyl radical or, together with R 2 can represent a phthaloyl radical, and the phthaloyl radical is optionally removed by hydrazinolysis and the resultant tetraester is saponified to the corresponding diester or acid of general formula I, whereby, under these conditions, the acyl or phthaloyl radical used is simultaneously split off; or c) when n is 0, a compound of the general formula:- R R R 3 !5 ii R 1 R 3 R SN C C (CH 2 OH (IX) R R R4 R 6 in which R 1 -R 6 and m have the above-given meanings, is reacted with an epoxide of the general formula:- 0 O. p(0 7 P(OR') SP(OR') 9 II 0 in which R 7 R 8 and R' have the above-given meanings, and the resultant diphosphonic acid derivative of the general formula:- -46- 0 R R 3 R 5 R 7 P(OR') N C C (CH 2 -0-C C OH (XI) R 2 R R 6 R P(OR') 0 8 wherein R 1 -R 8 R' and m have the above-given meanings, is, if desired, saponified to the corresponding diester or acid; or III. when X in general formula I is an -NR10R11 radical, a carboxylic acid derivative of the general formula:- R R R R 1 R3 .5 R7 SN C C (CH 2 -0-(CH2) n C -A (XII) SR4 R 6 R 4 6 8 in which R 1 -R 8 m and n have the above-given meanings and A is a nitrile, imino ether or a -CONR 10 R 1 1 radical, R 1 0 and R 1 1 having the above-given meanings, is reacted with a phosphorus compound of the general formula:- PT 3 (XIII) Sin which T is a halogen atom, a hydroxyl group or OR', R' having the above-given meaning, and optionally subsequently saponified; or IV. when X in general formula I is a hydrogen atom, a) a compound of the general formula:- A -47- RI R R N C C (CH2) U (XIV) R2 n 2 R 4 R 6 4 6 in which R 1 -R 6 and m have the above-given meanings and R1 can also be an acyl radical or, together with R, 1R29 can be a phthaloyl radical and U is a reactive group, M is reacted with a diphosphonic acid derivative of the i general formula:- 0 R 7 P(OR') HO (CH 2 C CH (XV) R 8 P(OR') 2 0 in which R 7 R 8 R' and n have the above-given meanings, and the phthaloyl radical is, if desired, removed by hydrazinolysis and the tetraester formed is optionally saponified to the corresponding diester or acid, whereby, under these conditions, the acyl or phthaloyl radical used as protective group, is split off simultaneously; or b) a compound of the general formula:- R R3 R R3 1. N C C (CH 2 OH (IX) R 2 1- 2 m R 4 R 6 in which R -R 6 and m have the above-given meanings, is added to a compound of the general formula:- j -48- 0 R 7 P(OR') 2 SC C (XVI) R 8 P(OR') 2 0 in which R 7 R 8 and R' have the above-given meanings, and the resultant tetraester is optionally saponified to the corresponding diester or acid; or c) a compound of the general formula:- R R R R 7 1 N -C -C (CH 2 -O-(CH2) C U (XVII) 2 m 2 n 2 R 4 R6 R 8 in which R 1 -R 8 U, m and n have the above-given meanings and R 1 can also be an acyl radical or, together with R 2 can be a phthaloyl radical, is reacted with a diphosphonic acid derivative of the I general formula:- 0 SP(OR')2 H 2 C (XVIII) 0 2 P(OR' 0 in which R' has the above-given meaning, the phthaloyl radical is, if desired, removed by hydrazinolysis and the resultant tetraester is, if desired, saponified to the corresponding diester or acid, whereby, under i ;i -i ~I i ~l n D f Iji f i i ;:i j :u /:j :I i i ii 1~ ii :i.I I' iB:h ci j- -49- these conditions, the acyl or phthaloyl radical used as protective group is simultaneously split off; or d) when R 8 is a hydrogen atom, a compound of the general formula:- R1 R 2 R3 R 5 R 7 SN C C (CH 2 -0-(CH 2 C C R 4 R 6 4 6 P(OR 9 2 P(OR 9 )2 9 (XIX) in which R 1 -R 7 R 9 m and n have the above-given meanings, whereby R 1 can also be an acyl radical, is catalytically hydrogenated, and subsequently, the resultant tetraester is optionally saponified to the corresponding diester or acid, whereby acyl radicals possibly present can thereby also be split off at the same time and the free acid is, if desired, converted into a pharmacologically acceptable salt; with the proviso that R 1 and R 2 together with the nitrogen atom cannot form a piperidine or piperazine ring and R 1 and R 3 as well as R 1 and R 5 together with the nitrogen atom cannot form a piperidine ring. 4. Process according to claim 3 for the preparation of compounds according to claim 1, substantially as hereinbefore described and exemplified. Compounds according to claim 1, whenever prepared by the process according to claim 3 or 4. 6. Pharmaceutical compositions containing at least one compound according to any of claims 1, 2 and 5, in addition to conventional carrier and adjuvant materials. 11I1 F- rr- 7. A method for the treatment of calcium metabolism disturbances in a mammal in need thereof comprising administering to said mammal an effective amount of the compounds according to any one of claims 1, 2 or 8. The method according to claim 7 wherein the mammal is a human. DATED this 14th day of June, 1991 BOEHRINGER MANNHEIM GmbH by DAVIES COLLISON Patent Attorneys for the applicant(s) 'V C rII ,IC 910618,ejhspe.021 ,37287.spe,5O AU37287/89A 1988-07-05 1989-07-04 Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them Ceased AU616283B2 (en) Applications Claiming Priority (2) Application Number Priority Date Filing Date Title DE3822650 1988-07-05 DE3822650A DE3822650A1 (en) 1988-07-05 1988-07-05 NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS Publications (2) Publication Number Publication Date AU3728789A AU3728789A (en) 1990-01-11 AU616283B2 true AU616283B2 (en) 1991-10-24 Family ID=6357951 Family Applications (1) Application Number Title Priority Date Filing Date AU37287/89A Ceased AU616283B2 (en) 1988-07-05 1989-07-04 Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them Country Status (22) Country Link US (1) US5002937A (en) EP (1) EP0350002B1 (en) JP (1) JPH0256492A (en) KR (1) KR900001711A (en) CN (1) CN1039248A (en) AT (1) ATE84538T1 (en) AU (1) AU616283B2 (en) CA (1) CA1334409C (en) DD (1) DD287508A5 (en) DE (2) DE3822650A1 (en) DK (1) DK327689A (en) ES (1) ES2046383T3 (en) FI (1) FI893262A (en) HU (1) HU205127B (en) IL (1) IL90804A (en) MX (1) MX16658A (en) NO (1) NO892762L (en) NZ (1) NZ229787A (en) PL (1) PL158956B1 (en) PT (1) PT91053B (en) RU (1) RU1823875C (en) ZA (1) ZA895069B (en) Cited By (1) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title AU660672B2 (en) * 1991-05-13 1995-07-06 E.R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method Families Citing this family (36) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate JP3141053B2 (en) * 1991-12-26 2001-03-05 アベンティス ファーマ株式会社 Bisphosphonic acid derivatives TW237386B (en) * 1992-04-15 1995-01-01 Ciba Geigy US5283057A (en) * 1992-04-24 1994-02-01 The Procter & Gamble Company Risedronate in oral compositions DE69319732T2 (en) * 1992-05-29 1999-02-11 Procter & Gamble Pharma QUATERNAR NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR THE TREATMENT OF ABNORMAL CALCIUM AND PHOSPHATE METABOLISM AND DENTALIZATION TW258729B (en) * 1992-06-22 1995-10-01 Ciba Geigy HUT72307A (en) 1993-03-08 1996-04-29 Eisai Co Ltd Phosphonic acid derivatives JPH06298779A (en) * 1993-04-15 1994-10-25 Hoechst Japan Ltd Heterocyclic iminobismethylenebisphosphonic acid derivaitve US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations DE19962924A1 (en) 1999-12-24 2001-07-05 Bayer Ag Substituted oxazolidinones and their use US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance PE20011061A1 (en) 2000-02-01 2001-11-20 Procter & Gamble SELECTIVE CRYSTALLIZATION OF 3-PYRIDYL-1-HYDROXY-ETHYLIDEN-1,1-BISPHOSPHONIC SODIUM ACID AS HEMIPENTAHYDRATE OR MONOHYDRATE PE20011065A1 (en) * 2000-02-01 2001-11-21 Procter & Gamble PROCESS FOR MANUFACTURING GEMINAL BISPHOSPHONATES BR0110618A (en) 2000-05-05 2003-04-29 Hoffmann La Roche Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts DE10129725A1 (en) * 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones WO2003055496A1 (en) * 2001-12-21 2003-07-10 The Procter & Gamble Company Method for the treatment of bone disorders MXPA04009586A (en) * 2002-05-10 2005-01-11 Hoffmann La Roche Bisphosphonic acid for the treatment and prevention of osteoporosis. SG174628A1 (en) * 2002-12-20 2011-10-28 Hoffmann La Roche High dose ibandronate formulation DE10300111A1 (en) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Process for the preparation of 5-chloro-N - ({(5S) -2-oxo-3- [4- (3-oxo-4-morpholinyl) phenyl] -1,3-oxazolidin-5-yl} methyl ) -2-thiophenecarboxamide EP1656386B1 (en) * 2003-08-21 2009-12-09 Sun Pharmaceuticals Industries Ltd. A process for preparation of bisphosphonic acid compounds DE10355461A1 (en) 2003-11-27 2005-06-23 Bayer Healthcare Ag Solid, high bioavailabilty oral formulations of N-substituted 5-chloro-2-thiophene-carboxamide derivative in hydrophilized form, useful for combating thrombo-embolic diseases US7214818B2 (en) 2004-10-29 2007-05-08 Hoffmann-La Roche Inc. Method for synthesizing bisphosphonate DE102004062475A1 (en) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Solid, orally administrable, modified release pharmaceutical dosage forms EP1685841A1 (en) * 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders DE102005045518A1 (en) * 2005-09-23 2007-03-29 Bayer Healthcare Ag New 5-thienylaminocarbonylmethyl-oxazolidin-2-one derivatives, useful for treating and preventing thromboembolic disease, are selective inhibitors of coagulation factor Xa DE102005047561A1 (en) 2005-10-04 2007-04-05 Bayer Healthcare Ag Drug delivery system, useful to treat and/or prevent e.g. thromboembolic disease, comprises 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxo-4-morpholinyl)-phenyl)-1,3-oxazolidine-5-yl)-methyl)-2-thiophene carboxamide with fast release active substance US8188270B2 (en) 2005-10-04 2012-05-29 Bayer Schering Pharma Aktiengesellschaft Polymorphous form of 5-chloro-N-({(5S)-2-oxo-3[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxamide DE102005047558A1 (en) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Combination therapy of substituted oxazolidinones for the prophylaxis and treatment of cerebral circulatory disorders DE102005048824A1 (en) * 2005-10-10 2007-04-12 Bayer Healthcare Ag Treatment and prophylaxis of microangiopathies DE102006051625A1 (en) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Combination therapy of substituted oxazolidinones HUE026660T2 (en) * 2007-04-11 2016-07-28 Hoffmann La Roche Multi step synthesis of ibandronate EP2643291A2 (en) * 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds US8748097B1 (en) 2011-12-02 2014-06-10 President And Fellows Of Harvard College Identification of agents for treating calcium disorders and uses thereof PL407922A1 (en) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością New bisphosphonates and their applications WO2017041720A1 (en) 2015-09-09 2017-03-16 清华大学 Mevalonate pathway inhibitor as highly-effective vaccine adjuvant CN111225672B (en) 2017-10-16 2023-09-29 清华大学 Mevalonate pathway inhibitor and pharmaceutical composition thereof Citations (2) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title AU8269487A (en) * 1986-12-19 1988-06-23 Norwich Eaton Pharmaceuticals, Inc. Novel heterocycle-substituted diphosphonate compounds pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism AU598279B2 (en) * 1986-07-11 1990-06-21 Boehringer Mannheim Gmbh New diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them Family Cites Families (12) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title DE3365492D1 (en) * 1982-01-27 1986-10-02 Schering Ag Diphosphonic acid derivatives and pharmaceutical preparations containing them DE3203308A1 (en) * 1982-01-27 1983-07-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen DIPHOSPHONIC ACID DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM FR2531088B1 (en) * 1982-07-29 1987-08-28 Sanofi Sa ANTI-INFLAMMATORY PRODUCTS DERIVED FROM METHYLENEDIPHOSPHONIC ACID AND THEIR PREPARATION METHOD GB8419489D0 (en) * 1984-07-31 1984-09-05 Leo Pharm Prod Ltd Chemical compounds DE3428524A1 (en) * 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds US4687768A (en) * 1984-12-21 1987-08-18 The Procter & Gamble Company Certain hexahydroindan-2,2-diphosphonic acids useful in treating diseases associated with abnormal calcium and phosphate metabolism DE3512536A1 (en) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS GB8615916D0 (en) * 1986-06-30 1986-08-06 Amersham Int Plc Bone-seeking complexes of technetium-99m DE3626058A1 (en) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS US4868164A (en) * 1986-12-19 1989-09-19 Norwich Eaton Pharmaceuticals, Inc. Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism EP0317505A1 (en) * 1987-11-13 1989-05-24 Ciba-Geigy Ag Azacycloalkylalkandiphosphonic acids 1988 1988-07-05 DE DE3822650A patent/DE3822650A1/en not_active Withdrawn 1989 1989-06-29 IL IL9080489A patent/IL90804A/en not_active IP Right Cessation 1989-06-30 NZ NZ229787A patent/NZ229787A/en unknown 1989-06-30 DD DD89330232A patent/DD287508A5/en not_active IP Right Cessation 1989-06-30 DK DK327689A patent/DK327689A/en not_active Application Discontinuation 1989-06-30 MX MX1665889A patent/MX16658A/en unknown 1989-07-04 PL PL1989280399A patent/PL158956B1/en unknown 1989-07-04 NO NO89892762A patent/NO892762L/en unknown 1989-07-04 AU AU37287/89A patent/AU616283B2/en not_active Ceased 1989-07-04 HU HU893371A patent/HU205127B/en not_active IP Right Cessation 1989-07-04 ZA ZA895069A patent/ZA895069B/en unknown 1989-07-04 RU SU894614502A patent/RU1823875C/en active 1989-07-04 CA CA000604669A patent/CA1334409C/en not_active Expired - Fee Related 1989-07-04 FI FI893262A patent/FI893262A/en not_active Application Discontinuation 1989-07-04 PT PT91053A patent/PT91053B/en not_active IP Right Cessation 1989-07-05 AT AT89112263T patent/ATE84538T1/en not_active IP Right Cessation 1989-07-05 ES ES198989112263T patent/ES2046383T3/en not_active Expired - Lifetime 1989-07-05 KR KR1019890009525A patent/KR900001711A/en not_active Application Discontinuation 1989-07-05 CN CN89104675A patent/CN1039248A/en active Pending 1989-07-05 JP JP1172089A patent/JPH0256492A/en active Pending 1989-07-05 DE DE8989112263T patent/DE58903263D1/en not_active Expired - Fee Related 1989-07-05 EP EP89112263A patent/EP0350002B1/en not_active Expired - Lifetime 1989-07-05 US US07/375,747 patent/US5002937A/en not_active Expired - Fee Related Patent Citations (3) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title AU598279B2 (en) * 1986-07-11 1990-06-21 Boehringer Mannheim Gmbh New diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them AU598569B2 (en) * 1986-07-11 1990-06-28 Boehringer Mannheim Gmbh Diphosphonic acid derivatives and medicines containing them AU8269487A (en) * 1986-12-19 1988-06-23 Norwich Eaton Pharmaceuticals, Inc. Novel heterocycle-substituted diphosphonate compounds pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism Cited By (1) * Cited by examiner, † Cited by third party Publication number Priority date Publication date Assignee Title AU660672B2 (en) * 1991-05-13 1995-07-06 E.R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method Also Published As Publication number Publication date NZ229787A (en) 1991-09-25 DK327689A (en) 1990-01-06 JPH0256492A (en) 1990-02-26 CN1039248A (en) 1990-01-31 NO892762L (en) 1990-01-08 AU3728789A (en) 1990-01-11 RU1823875C (en) 1993-06-23 CA1334409C (en) 1995-02-14 ES2046383T3 (en) 1994-02-01 ATE84538T1 (en) 1993-01-15 DE58903263D1 (en) 1993-02-25 HU205127B (en) 1992-03-30 DK327689D0 (en) 1989-06-30 US5002937A (en) 1991-03-26 DE3822650A1 (en) 1990-02-01 PT91053B (en) 1995-01-31 NO892762D0 (en) 1989-07-04 PT91053A (en) 1990-02-08 IL90804A0 (en) 1990-01-18 PL158956B1 (en) 1992-10-30 IL90804A (en) 1994-04-12 MX16658A (en) 1993-11-01 KR900001711A (en) 1990-02-27 EP0350002A1 (en) 1990-01-10 HUT50842A (en) 1990-03-28 EP0350002B1 (en) 1993-01-13 FI893262A0 (en) 1989-07-04 ZA895069B (en) 1990-04-25 DD287508A5 (en) 1991-02-28 FI893262A (en) 1990-01-06 Similar Documents Publication Publication Date Title AU616283B2 (en) 1991-10-24 Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them KR950008997B1 (en) 1995-08-10 1-hydroxy-3-(n-methyl-n-propylamino)propane-1,1-diphosphonic acid, process for its preparation and medicines containing this compound US4719203A (en) 1988-01-12 Diphosphonic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them FI87223C (en) 1992-12-10 Process for the preparation of novel pharmacologically active alkyl diphosphonic acid derivatives EP0273190B1 (en) 1991-04-17 Diphosphoric acid derivatives, process for their preparation and pharmaceuticals containing them NZ246152A (en) 1995-12-21 3-(aminoalkyl- and azaheterocyclylalkyl)-2-phosphonosuccinic acid derivatives and pharmaceutical compositions CA1336978C (en) 1995-09-12 Bisphosphonates US5206253A (en) 1993-04-27 Disphosphonic acid derivatives, processes for their production and pharmaceutical preparations containing these compounds JPH09502158A (en) 1997-03-04 Novel acyclic amidine group-containing diphosphonic acid derivative, process for producing the same and pharmaceuticals containing them Legal Events Date Code Title Description 2001-02-08 MK14 Patent ceased section 143(a) (annual fees not paid) or expired
Download PDF in English